Company News, Patents

Dermala Expands Patent Roster with Latest Eczema Treatment Technology

Technology uses novel derivatives of postbiotic metabolites derived from C. acnes in the human skin microbiome to inhibit S. aureus.

Author Image

By: Christine Esposito

Editor-in-Chief

Consumer dermatology company Dermala, Inc. has been awarded a US patent (No. 11,364,214) for compositions and method for treating eczema. This is the fourth patent in the San Diego-based company’s expanding intellectual property (IP) portfolio. This latest patent covers using the human microbiome to treat and prevent atopic dermatitis (eczema) without using steroids or immunomodulators associated with side effects.

Dermala's patented technology uses novel derivatives of postbiotic metabolites derived from C. acnes in the human skin microbiome to inhibit S. aureus including the overgrowth of methicillin-resistant S. aureus, MRSA. These postbiotic derivatives activate on the skin in the presence of S. aureus and then act by directly killing S. aureus to prevent S. aureus overgrowth. In addition, they help correct the imbalance in the microbiome and strengthen the beneficial bacteria present in the skin microbiome thus inhibiting S. aureus naturally. These microbiome-derived postbiotic derivatives can be combined with other ingredients to significantly increase the efficacy of the treatment without using steroids and causing side effects. 

The patent is part of Dermala’s IP portfolio that covers using the human microbiome for conditions including acne, eczema, and skin aging, as well as data analytics-driven treatment personalization and optimization. 

Dermala took home top honors in a Colgate Connect Challenge earlier this year.

Keep Up With Our Content. Subscribe To Happi Newsletters